A Comparison between Three Serological Stratification About Early Screening of Gastric Cancer

Ni, Dongqiong; Lv, Bin; Bao, Haibiao; Jin, Haifeng; Zhao, Jing; Xu, Yi; Huang, Xuan

doi:10.2139/ssrn.3384866

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ABC method was divided into four groups (Group A: H. pylori (-) and PG (-); Group B: H. pylori (+) and PG (-); Group C: H. pylori (+) and PG (+); Group D: H. pylori (-) and PG (+)) according to the levels of serum anti- H. pylori IgG antibody, PG I and PG II, and PG I ≤ 70 ug/L and PG I/II ≤3 were classified as PG positive [ 12 ]. The new ABC method was divided into three groups (Group A: G-17 (-) and PG (-); Group B: G-17 (+) and PG (-), or G-17 (-) and PG (+); Group C: G-17 (+) and PG (+)) according to the levels of serum PG I, PG II and G-17, and PG I ≤ 70 ug/L and PG I/II ≤7 were classified as PG positive, G-17 ≤ 1 pmol/L or G-17 ≥ 15 pmol/L were classified as G-17 positive [ 13 ].…”

Section: Methodsmentioning

confidence: 99%

“…Most patients are found to have advanced gastric cancer, while the 5-year survival rate of early gastric cancer after radical resection is over 90% [ 11 ]. Therefore, many scholars have constructed early screening models for gastric cancer based on serological examination, including the ABC method and the new ABC method [ 12 , 13 ]. A new screening method proposed by Li et al.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of the prevalence and risk factors of Helicobacter pylori infection and the value of different gastric cancer screening methods in a low-risk region of gastric cancer in China

Liao,

Zhu,

Zhu

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background The aim of this current study was to identify the prevalence and risk factors of H. pylori infection in the low-risk area of gastric cancer in China, and evaluate the value of different gastric cancer screening methods. Methods An epidemiological study was conducted in Yudu County, Jiangxi, China, and participants were followed up for 6 years. All participants completed a questionnaire, laboratory tests and endoscopy. Patients were divided into H. pylori positive and negative groups, and risk factors for H. pylori infection were identified using multivariate logistic regression analysis. Results A total of 1962 residents were included, the prevalence of H. pylori infection was 33.8%. Multivariate analysis showed that annual income ≤20,000 yuan (OR: 1.44, 95% CI: 1.18–1.77, p < 0.001), loss of appetite (OR: 1.71, 95% CI: 1.29-2.26, p < 0.001), PG II >37.23 ng/mL (OR: 2.11, 95% CI: 1.50–2.97, p < 0.001), G-17 > 1.5 and ≤5.7 pmol/L (OR: 2.52, 95% CI: 1.93–3.30, p < 0.001), and G-17 > 5.7 pmol/L (OR: 1.96, 95% CI: 1.48–2.60, p < 0.001) were risk factors of H. pylori infection, while alcohol consumption (OR: 0.70, 95% CI: 0.54–0.91, p = 0.006) was a protective factor. According to the new gastric cancer screening method, the prevalence of low-grade intraepithelial neoplasia in the low-risk group, medium-risk group and high-risk group was 4.4%, 7.7% and 12.5% respectively ( p < 0.001). Conclusions In a low-risk area of gastric cancer in China, the infection rate of H. pylori is relatively low. Low income, loss of appetite, high PG II, and high G-17 were risk factors for H. pylori infection, while alcohol consumption was a protective factor. Moreover, the new gastric cancer screening method better predicted low-grade intraepithelial neoplasia than the ABC method and the new ABC method.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Investigation of the prevalence and risk factors of Helicobacter pylori infection and the value of different gastric cancer screening methods in a low-risk region of gastric cancer in China

Liao,

Zhu,

Zhu

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

show abstract

“…It is recommended to not overlook population characteristics such as age, sex, and dietary habits, in addition to the provided laboratory indicators. Furthermore, the joint method—a predictive model combining both the ABC method and population characteristics—has shown promising results with an area under the curve of 0.76 when calibrated 120 , 121 .…”

Section: Biomarker Screening For Early Gastric Cancermentioning

confidence: 99%

Global progress and future prospects of early gastric cancer screening

Huang,

Shao,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastric cancer is a prevalent malignancy that poses a serious threat to global health. Despite advances in medical technologies, screening methods, and public awareness, gastric cancer remains a significant cause of morbidity and mortality worldwide. Early gastric cancer frequently does not present with characteristic symptoms, while advanced stage disease is characterized by a dismal prognosis. As such, early screening in gastric cancer is of great importance. In recent years, advances have been made globally in both clinical and basic research for the screening of early gastric cancer. The current predominant screening methods for early gastric cancer include imaging screening, endoscopic screening and serum biomarker screening. Imaging screening encompasses upper gastrointestinal barium meal, multidimensional spiral computed tomography (MDCT), Magnetic resonance imaging (MRI), and ultrasonography. Endoscopic screening methods include white light endoscopy, chromoendoscopy, computed virtual chromoendoscopy, and other endoscopic techniques like endocytoscopy, confocal laser endomicroscopy, optical coherence tomography and so on. Biomarkers screening involves the assessment of conventional biomarkers such as CEA, CA19-9 and CA72-4 as well as more emerging biomarkers such as peptides (PG, G-17, GCAA, TAAs and others), DNA (cfDNA, DNA methylation, MSI), noncoding RNA (miRNA, lncRNA, circRNA, and tsRNA) and others. Each screening method has its strengths and limitations. This article systematically summarizes worldwide progress and future development of early gastric cancer screening methods to provide new perspectives and approaches for early diagnostic and treatment advancements in gastric cancer worldwide.

show abstract

“…A new GC score system based on age, sex, PG, G-17, and H pylori antibodies was introduced in China’s early GC screening process expert consensus [ 5 ]. While this new GC score system might exhibit improved prediction performance [ 7 ], the cost-benefit of its clinical application needs to be analyzed. Plasma tumor markers, such as carcinoembryonic antigen, cancer antigen (CA) 19-9, CA 72-4, CA 125, and CA 242, are linked to patient prognosis but are not suitable for early cancer detection [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study

Han,

Wei,

Wang

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. Objective This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. Methods This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model Results Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. Conclusions This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. Trial Registration ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910 International Registered Report Identifier (IRRID) DERR1-10.2196/48247

show abstract

A Comparison between Three Serological Stratification About Early Screening of Gastric Cancer

Cited by 5 publications

References 0 publications

Investigation of the prevalence and risk factors of Helicobacter pylori infection and the value of different gastric cancer screening methods in a low-risk region of gastric cancer in China

Investigation of the prevalence and risk factors of Helicobacter pylori infection and the value of different gastric cancer screening methods in a low-risk region of gastric cancer in China

Global progress and future prospects of early gastric cancer screening

Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study

Contact Info

Product

Resources

About